Table 2 Treatment employed, tumors’ response after NAC, and 30-day surgical complications

NAC type

 Gemceitabine/cisplatin

69

95.8

 Gemceitabine

1

1.4

 Carboplatin

2

2.8

NAC number of cycles; median (range)

 3(1–8)

  1–2

7

9.7

  3–4

58

80.6

  5–8

7

9.7

Radiological tumor size response^a

 CR

3

4.2

 PR

44

61.1

 SD

11

15.3

 PD

14

19.4

Radiological Lymph node response^a

 PR

12

16.7

 SD

50

69.4

 PD

10

13.9

Type of radical surgery

 Open radical cystectomy

60

83.3

 Laparoscopic radical cystectomy

6

8.3

 Anterior pelvic exentration

5

6.9

 Robotic radical cystectomy

1

1.4

Type of urinary diversion

 Ileal conduit

53

73.6

 Orthotopic neobladder

13

18.1

 Cutaneous ureterostomy

4

5.5

 Rectal bladder

2

2.8

30-day morbidity/mortality

 No

51

70.8

 Morbidity

16

22.2

 Mortality

5

7.0

30-day morbidity/mortality causes (n = 21)

 Intestinal fistula

7

33.3

 Burst abdomen

6

28.6

 Renal impairment

3

14.3

 Paralytic ileus

3

14.3

 Wound infection

2

9.5